NextGen Scientific LLC has issued an updated announcement to correct inaccurate information in a previously distributed press release regarding the structure and use of proceeds from its current capital raise. The company is raising $10 million from accredited investors in a Regulation D, Rule 506(c) private placement offering.
Proceeds from the offering will be used to acquire up to 3.1% ownership in Ionics Life Sciences Limited and its subsidiaries, including Genzada Pharmaceuticals USA and Hyatt Life Sciences. This investment provides exposure to both clinical-stage drug development and a growing, revenue-generating nutritional supplements business.
Genzada Pharmaceuticals USA is an early-stage biotechnology company focused on oncology drug development. Its lead oral compound, GZ17-6.02, has demonstrated safety and efficacy in preclinical and clinical studies and is currently being evaluated in a metastatic prostate cancer study at Virginia Commonwealth University. According to the company's Chief Operating Officer Cameron West, MD, FAAD, the Phase I dose escalation study for GZ17-6.02 showed promising biological effect against a broad array of cancer types.
The company's second clinical-stage asset, GZ21T, is a topical therapy for cancerous and precancerous skin conditions expected to receive regulatory approval in Q1 2026 to initiate a Phase 1b/2a clinical trial in actinic keratosis patients in Sweden and the Netherlands. West expressed optimism about GZ21T's potential to deliver significant results in dermatologic conditions based on preclinical data and preliminary safety profiles.
Capital raised will primarily support clinical and preclinical programs for both GZ17-6.02 and GZ21T, as well as related drug manufacturing and development activities. Specific allocations include clinical studies of GZ21T in atopic dermatitis, pre-clinical advancement, and the clinical and pre-clinical development of GZ17-6.02 for prostate and breast cancer.
Hyatt Life Sciences represents the revenue-generating component of the investment, operating as a nutraceutical and botanical sciences enterprise specializing in science-based dietary supplements. The company integrates traditional botanical knowledge with modern scientific validation within the rapidly expanding global nutraceuticals market. Proceeds will also support targeted marketing initiatives for the company's supplement portfolio.
NextGen Scientific describes itself as a life sciences company focused on advancing oncology and dermatology drug development while participating in the commercialization of science-backed wellness products. Through its strategic investment in Ionics Life Sciences and its subsidiaries, NextGen is building a diversified healthcare platform designed to generate long-term value through clinical innovation and active revenue streams. More information about the company is available at https://investinnextgen.com/.
The announcement includes standard forward-looking statements and disclaimers, noting that the communication is not an offer to buy or sell securities and that any offering would be made through official offering documents. The company's full disclaimers can be found at https://investinnextgen.com/disclaimers/.
